Agmatine has received considerable attention recently. Available evidence suggests that agmatine functions as a neurotransmitter and inhibits, via induction of antizyme, cellular proliferation. Because of its positive charge, agmatine will not appreciably cross cellular membranes by simple diffusion. Indeed, all physiological models require a channel or transporter protein in the plasma membrane to effect inactivation or nonexocytotic release of agmatine. However, a transport mechanism for agmatine has not been identified on a molecular level so far. In the present study, the non-neuronal monoamine transporters, organic cation transporter (OCT) 1, OCT2, and extraneuronal monoamine transporter (EMT) (gene symbols SLC22A1-A3), both from human and rat, were examined, stably expressed in 293 cells, for [
SLC22A1-A3)
, both from human and rat, were examined, stably expressed in 293 cells, for [
3 H]agmatine transport. Our results indicate that OCT2 and EMT, but not OCT1, efficiently translocate agmatine. The structural homolog putrescine was not accepted as substrate. Uptake of agmatine via EMT and OCT2 was saturable, with K m values of 1 to 2 mM. The affinity of OCT1 was 10-fold lower. Carrier-mediated efflux of agmatine was documented in a trans-stimulation experiment. Finally, uptake of agmatine increased dramatically with increasing pH. Thus, only the singly charged species of agmatine is accepted as substrate. In conclusion, both EMT and OCT2 must be considered for the control of agmatine levels in rat and human.
In recent years, agmatine has been recognized as an extracellular signaling substance in mammalia. Agmatine [1-(4-aminobutyl) guanidine] is an amine, synthesized by decarboxylation of L-arginine by arginine decarboxylase. Arginine decarboxylase activity is associated with mitochondrial membranes and is most prevalent in kidney, liver, and brain (Lortie et al., 1996) . Agmatine is present in plasma and is widely but unevenly distributed in mammalian tissue (Raasch et al., 1995) .
There is evidence that agmatine acts as an antiproliferative molecule through induction of the protein antizyme (Satriano et al., 1998; Babal et al., 2001) . Antizyme inhibits ornithine decarboxylase and hence polyamine (putrescine, spermine, and spermidine) biosynthesis. At the same time, antizyme suppresses polyamine uptake. Concerted intracellular polyamine depletion eventually leads to growth arrest. Thus, agmatine has been considered a tumor suppressor in the control of cellular proliferation (Satriano et al., 1999) . In addition, agmatine might serve as a neurotransmitter or neuromodulator. It is synthesized in specific regions of the brain, stored in synaptic vesicles, released by depolarization, and inactivated by agmatinase and diamine oxidase (Li et al., 1994) . Moreover, agmatine binds to ␣ 2 -adrenoceptors and imidazoline binding sites, and blocks NMDA receptor channels and other ligand-gated cation channels. It also inhibits nitric oxide synthase and induces release of peptide hormones. Although the precise function of endogenously released agmatine in the central nervous system is presently still unclear, there is obvious therapeutic potential in the treatment of chronic pain (hyperalgesia), addiction, and brain injury (Reis and Regunathan, 2000) .
Since agmatine carries one or two positive charges at physiological pH, it will not appreciably cross cellular membranes by simple diffusion. Thus, all physiological models require the presence of a channel or transporter protein in the plasma membrane to translocate agmatine. This will allow inactivation of the transmitter by uptake into metabolizing cells, e.g., in the central nervous system, or nonexocytotic release from agmatine-producing cells, e.g., in the kidney. However, so far, a transport mechanism for agmatine has not been identified on a molecular level. We have considered the non-neuronal monoamine transporters EMT, OCT2, and OCT1 (Grü ndemann et al., 1994 (Grü ndemann et al., , 1998b Okuda et al., 1996) as likely candidates. In particular, in a recent study we have demonstrated that OCT2 specifically and efficiently transports guanidine, a main component of agmatine (Grü ndemann et al., 1999) . The aim of the current study, therefore, was to examine whether the non-neuronal monoamine transporters accept agmatine as a substrate. Our results indicate that OCT2 and EMT, but not OCT1, efficiently translocate agmatine across the plasma membrane and may contribute to both release and inactivation of this transmitter.
Materials and Methods

Construction of Expression Vectors for OCT1h and OCT2h.
For the cloning of OCT1h, total RNA from a human liver biopsy sample was prepared as described (Grü ndemann et al., 1997) . A cDNA covering the entire open reading frame was generated by RT-PCR with Pwo Polymerase (Roche Diagnostics, Mannheim, Germany) and with primers 5Ј-GAG AGA GAG GAT CCG CCA CCA TGC CCA CCG TGG ATG ACA TT (forward primer, BamHI site underlined; this primer introduces a perfect Kozak sequence) and 5Ј-GAG AGA GAC TCG AGC TGC AGA GGA TAA CTC CAT CTT (reverse primer, XhoI site underlined). The amplicon (1.8 kilobases) was cloned, completely sequenced, and eventually assembled into the BamHI and XhoI sites of pcDNA3 (Invitrogen, NV Leek, The Netherlands) to yield pcDNA3OCT1h. The amino acid sequence of our OCT1h clone is identical to the published sequence (GenBank accession number X98332) except for a single amino acid substitution, M408V. Sequencing of three independent clones uniformly revealed the same underlying base disparity, 1294AϾG.
Total RNA from human kidney (BD Biosciences Clontech, Palo Alto, CA) was used for the cloning of OCT2h. A cDNA covering the entire open reading frame was generated by RT-PCR with LA Taq mixture (Takara Bio, Shiga, Japan) and with primers 5Ј-GAG AGA GAG GAT CCG CCA CCA TGC CCA CCA CCG TGG ACG AT (forward primer, BamHI site underlined; this primer also introduces a Kozak sequence) and 5Ј-GAG AGA GAC TCG AGG GCT CAG GGG TAA GTT TGG TT (reverse primer, XhoI site underlined). The amplicon (1.8 kilobases) was cloned, completely sequenced, and eventually assembled into the BamHI and XhoI sites of pcDNA3 to yield pcDNA3OCT2h. The amino acid sequence of our OCT2h clone is identical to the published sequence (GenBank accession number X98333).
Cell Culture and Transfection. The 293 cells (ATCC CRL-1573), a transformed cell line derived from human embryonic kidney, were grown at 37°C in a humidified atmosphere (5% CO 2 ) in plastic culture flasks (Falcon 3112; BD Biosciences, Heidelberg, Germany). The medium was Dulbecco's modified Eagle's medium (31885-023; Invitrogen, Eggenstein, Germany) supplemented with 10% fetal calf serum (Invitrogen). Medium was changed every 2 to 3 days, and the culture was split every 7 days.
The 293 cells were transfected with supercoiled plasmid DNA by lipofection with the Tfx-50 reagent according to the protocol of the vendor (Promega, Mannheim, Germany). Stably transfected cells were then selected with geneticin (G418; Invitrogen) as described (Grü ndemann et al., 1997) . Expression of OCT1h and OCT2h was verified by RT-PCR and functional characterization.
Transport Assays. For measurement of uptake of radiolabeled solutes, cells were grown in surface culture on 60-mm polystyrol dishes (Nunclon 150288; NUNC A/S, Roskilde, Denmark) precoated with 0.1 g/l poly-L-ornithine in 0.15 M boric acid-NaOH, pH 8.4. Cells were used for uptake experiments at a confluence of at least 70%.
Uptake was measured at 37°C. After preincubation for at least 20 min in 4 ml of uptake buffer [125 mM NaCl, 25 mM HEPES-NaOH, pH 7.4, 5.6 mM (ϩ)glucose, 4.8 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM CaCl 2 , and 1.2 mM MgSO 4 ], the buffer was replaced with 3 ml of 3 H-labeled substrate (at 100 nM if not noted otherwise) in uptake buffer. Incubation was stopped (after 1 min if not noted otherwise) by rinsing the cells four times with each 4 ml of ice-cold uptake buffer. Subsequently, the cells were solubilized with 0.1% (v/v) Triton X-100 in 5 mM Tris-HCl, pH 7.4, and radioactivity was determined by liquid scintillation counting. If not noted otherwise, in this study all inhibitors were absent during preincubation.
Protein Determination. Protein was measured by a modification of the Bradford method (Zor and Selinger, 1996) with bovine serum albumin as standard.
Calculations and Statistics. Analysis of the time course of substrate accumulation was based on a one-compartment model as described earlier . A modification for uptake of agmatine into EMTh cells is given in the legend to Fig. 4 . Analysis of saturation curves and calculation of K i values have been reported previously .
To model the velocity of uptake as a function of pH (see Fig. 7 ), for 1-methyl-4-phenylpyridinium iodide (MPP ϩ ), a polynomial of the second degree was used: v ϭ a 0 ϩ a 1 ⅐ pH ϩ A 2 ⅐ pH 2 . For agmatine, it follows from S ϩ I ϭ 0.1 M (S ϭ concentration of agmatine with a single positive charge; I ϭ concentration of agmatine with two positive charges), pH ϭ pK a ϩ log (S/I), and
To correct for the pH dependence of the transporter as measured by the uptake of MPP ϩ (see above), the right half of the last equation was multiplied with (a 0 ϩ a 1 ⅐ pH ϩ a 2 ⅐ pH 2 )/(a 0 ϩ a 1 ⅐ 7.5 ϩ a 2 ⅐ 7.5 2 ). This effects a normalization relative to pH 7.5, which was chosen arbitrarily. All parameters were fitted by nonlinear regression.
Fitted parameters such as K m and K i values are given as geometric mean with 95% confidence interval. Arithmetic means are given with SEM. p values are from a two-tailed unpaired t test.
Drugs. Radiotracers used were agmatine (H-3, 2220 Bq/pmol; ART-608; American Radiolabeled Chemicals, St. Louis, MO), 1-methyl-4-phenylpyridinium iodide (H-3, 2200 Bq/pmol; ART-150; American Radiolabeled Chemicals), and putrescine (H-3, 2960 Bq/ pmol; ART-279, American Radiolabeled Chemicals). Unlabeled compounds were agmatine sulfate (10144-3; Aldrich Chemical Co., Steinheim, Germany), MPP ϩ (D-048; Sigma/RBI, Natick, MA), and putrescine (32810; Fluka, Buchs, Switzerland). Disprocynium 24 (1,1Ј-diisopropyl-2,4-cyanine iodide) was synthesized as described previously . All other chemicals were of analytical grade.
Results
Cloning and Functional Expression of OCT1h and
OCT2h in 293 Cells. To comprehensively investigate agmatine transport with the three non-neuronal monoamine transporters OCT1, OCT2, and EMT both from human and rat, we have cloned OCT1h and OCT2h by RT-PCR with specific primers (see Materials and Methods for details) based on the published cDNA sequences (Gorboulev et al., 1997) . For functional expression, the cDNAs were inserted into the eukaryotic expression vector pcDNA3. The resulting plasmids were used to stably transfect 293 cells, our standard cell line for heterologous expression of non-neuronal monoamine transporters. Control cells were stably transfected with empty vector. Stably transfected cell lines expressing OCT1r, OCT2r, EMTr, and EMTh were available from previous studies (Breidert et al., 1998; Grü ndemann et al., 1998b Grü ndemann et al., , 1999 Grü ndemann et al., , 2002 .
To confirm functional expression of OCT1h and OCT2h, saturation of expressed uptake (i.e., total uptake minus total uptake into control cells) of MPP ϩ was examined (Fig. 1) . For OCT1h, the apparent Michaelis-Menten constant, K m , was 32 (95% confidence interval, 27-38) mol/l and the maximal uptake rate, V max , was 1.7 Ϯ 0.1 nmol min Ϫ1 mg of protein Ϫ1 . For OCT2h, the K m was 7.8 (6.2-9.8) mol/l and V max was 0.37 Ϯ 0.01 nmol min Ϫ1 mg of protein Ϫ1 . For both transporters, the Eadie-Hofstee plot is compatible with a single uptake mechanism.
Characterization of Agmatine Transport. The abovementioned cell lines were examined side-by-side in uptake experiments with 0.1 M [ 3 H]agmatine as substrate. Figure  2 , upper row, shows total uptake. To correct for uptake by control cells and for transporter number, the expressed uptake of agmatine was divided by the expressed uptake of [ 3 H]MPP ϩ , which was measured in paired assays. The normalized values (Fig. 2 , lower row) are directly proportional to transport efficiency (Grü ndemann et al., 1999) . Agmatine is a good substrate, with a factor of about 0.5 relative to MPP ϩ uptake, for EMTr and OCT2r, but transport by OCT1r was about 5-fold lower. An accordant pattern (although on a 4-fold lower level relative to MPP ϩ uptake) was observed with the human transporters. Here OCT1h was about 9-fold less efficient in the transport of agmatine than EMTh and OCT2h. In contrast to agmatine, uptake of [ 3 H]putrescine via EMTr, OCT2r, and OCT1r was not significantly different from control (Fig. 3) .
A detailed analysis of the time course of uptake of 0.1 M [ 3 H]agmatine into stably transfected cells expressing EMTh (Fig. 4) revealed that uptake was linear with time for at least 15 min, but decreased after about 2 h. Uptake into control cells was much lower, with rate constants for inwardly (k in ) and outwardly (k out ) directed agmatine fluxes of 1.0 Ϯ 0.1 l min Ϫ1 mg of protein Ϫ1 and 0.027 Ϯ 0.003 min Ϫ1 , respectively. To take into account the eventual decline in agmatine content, a modified fitting function was used (see Fig. 4 legend). For EMTh-expressing cells, the initial k in was 6.7 Ϯ 0.3 l min Ϫ1 mg of protein Ϫ1 and k out was 0.012 Ϯ 0.001 min Ϫ1 . The maximum uptake amounted to approximately 33 pmol mg of protein Ϫ1 . Based on an intracellular water space of 6.7 l mg of protein Ϫ1 (Martel et al., 1996) and a conjectured transfection efficiency of 100%, a 50-fold accumulation of agmatine relative to medium can be estimated. Uptake periods of 1 to 12 min were chosen for subsequent experiments to approximate initial rates of transport.
Expressed uptake of agmatine via OCT2 or EMT both from rat and human was saturable (Fig. 5a , mg of protein Ϫ1 ). Because of the low transport activity, the affinity for agmatine of OCT1 was determined by inhibition of MPP ϩ uptake (Fig. 5b , Table 1 ). The K i values for OCT1r and OCT1h were about 10 times higher than the K m values for OCT2 or EMT from the matching species. Thus, compared with OCT1, the affinity of OCT2 and EMT for agmatine is significantly higher.
A trans-stimulation experiment was made to verify that agmatine is actually transported across the plasma membrane. Cells expressing EMTh were preincubated for 20 min in uptake buffer with 1 mM unlabeled agmatine or MPP (Fig. 6) . On the basis of specific uptake, this acceleration of uptake of extracellular radiolabel by counter-transport of unlabeled intracellular substrate amounts to a factor of 1.9 Ϯ 0.2 (p ϭ 0.0016). With agmatine, stimulation was smaller (factor ϭ 1.4 Ϯ 0.2), yet still significant (p ϭ 0.029). Thus, it is safe to conclude that EMT and, by analogy, OCT2 are carriers of agmatine and not mere binding proteins or channels.
Since at physiological pH agmatine molecules with one or two positive charges are present in aqueous solution, we examined which species was the substrate for the non-neuronal monoamine transporters. Initial rates of uptake of 0.1 3 H]agmatine. Shown is the mean Ϯ S.E.M. (n ϭ 3). Exponential functions were fitted to the experimental data . Open circles, control cells, stably transfected with vector pcDNA3 (see main text for kinetic constants); filled circles, EMTh cells. Model: uptake (Fig. 7a) . For controls, uptake into cells transfected with empty vector and the pH dependence of MPP ϩ uptake was recorded in paired assays. Expressed uptake of the permanent monocation MPP ϩ increased slightly with increasing pH, as expected . By contrast, expressed uptake of agmatine was dramatically dependent on pH. The increase in velocity from pH 7.5 to 8.5 amounted to a factor of 7.2 Ϯ 0.5. The pK a of the amino group of agmatine calculated by nonlinear regression was 9.07 (8.84 -9.44). When agmatine uptake velocity corrected for pH dependence of the carrier protein (as measured with MPP ϩ as substrate) was plotted as a function of the concentration of singly charged agmatine (as calculated with the above-mentioned pK a ) (Fig. 7b) , a linear relation was found. In other words, transport velocity was directly proportional to the concentration of agmatine molecules with a single positive charge. This indicates that the agmatine species with two positive charges is no substrate of the non-neuronal monoamine transporters.
Discussion
In the present study, uptake of agmatine into control cells as a measure of basal permeability of the plasma membrane was low (expressed as clearance: 0.7 l min Ϫ1 mg of protein Ϫ1 , cf. Fig. 5 ). For comparison, the permeabilities of tyramine, MPP ϩ , histamine, and tetraethylammonium have been recorded in the same system as 3.2 (D. Grü ndemann, unpublished observation), 1.1, 0.5, and 0.2 l min Ϫ1 mg of protein Ϫ1 , respectively (Grü ndemann et al., 1999) . Thus, there is a definite need for an integral membrane protein to remove agmatine from the extracellular space or to release intracellular agmatine. However, so far, no such transporter has been identified on a molecular level. In the present study we report that the non-neuronal monoamine transporters EMT and OCT2, both from rat and human, efficiently transport agmatine (Fig. 2) . By comparison, OCT1 is conspicuously less efficient. The polyamine and spermine precursor putrescine (1,4-diaminobutane) is structurally related to agmatine (1-amino-4-guanidobutane), yet there was no significant transport by any of the (rat) non-neuronal monoamine transporters, which were highly active for MPP ϩ transport in paired assays (Fig. 3) . We conclude that OCT2 and EMT specifically accept agmatine as substrate, by virtue of its guanidinium residue. This, along with the low activity of (Table 1) , the affinities of EMT and OCT2 for agmatine are comparable with other monoamine transmitters such as noradrenaline, histamine, and 5-hydroxytryptamine (Breidert et al., 1998; Grü ndemann et al., 1998a,b) . Since V max values are relatively high, agmatine transport is in a low affinity, high turnover mode. The relatively inefficient transport of agmatine via OCT1 can be fully explained by reduced affinity (measured as K i values).
Our exemplary trans-stimulation experiment (Fig. 6 ) provides unambiguous proof that EMTh actually functions as transporter of agmatine, not just as channel or binding protein. Moreover, the experiment clearly documents that agmatine transport also works from inside to outside the cell. We expect similar results for the other non-neuronal monoamine transporters. Interestingly, in a previous study (Grü ndemann et al., 1999) trans-stimulation of OCT2r by histamine was much stronger (factor ϭ 3.2) than stimulation of EMTh in the present study by agmatine (factor ϭ 1.4), although both compounds gave similar V max values. To clarify this observation, we have examined whether EMTh transports the agmatine species with one or two positive charges. The guanidinium group at one end of agmatine can be considered a permanent cation (pK a Ͼ 13) in aqueous solution. We have not found a pK a for the amino group at the other end of agmatine in the literature, but for putrescine the corresponding pK a is 8.90 at 37°C. A result from the present study (Fig. 7a) suggests a similar value for agmatine (pK a ϭ 9.07). Thus, protonation of the amino group of agmatine depends very much on pH. For example, the fraction of agmatine molecules with a single positive charge will be 2.6% at pH 7.5 and 21% at pH 8.5. If agmatine 2ϩ was the substrate, then uptake velocity should decline with increasing pH. However, the opposite was observed. Agmatine uptake increased dramatically with increasing pH (Fig. 7a) and was directly proportional to agmatine ϩ concentration (Fig. 7b) . Thus, agmatine with a single positive charge is the sole substrate. This fully explains why trans-stimulation was lower with agmatine than with histamine: only a small fraction of intracellular agmatine will carry a single charge; i.e., the concentration of intracellular substrate is lower than with histamine. Agmatine 2ϩ , after all, could be an inhibitor of transport. However, since our data for the determination of K m and K i (Fig.  5) do not show any deviation from simple models, we suppose that agmatine 2ϩ has no significant affinity for the non-neuronal monoamine transporters. This has further implications. 1) Conversion of the concentration from total agmatine into agmatine ϩ indicates that agmatine ϩ is actually the best substrate known, for example, for OCT2r (the transport efficiency relative to MPP ϩ is 22 and 1.1 for agmatine ϩ or guanidine) and EMTh (6.1 and 0.47 for agmatine ϩ or histamine) (Grü ndemann et al., 1999) . It is unclear why the carriers from rat are more active in agmatine transport than their human counterparts (Fig. 2) . 2) Based on the same conversion of concentration, the affinity of OCT2 and EMT for agmatine ϩ is quite high: K m ϭ 20 -50 M (cf. Table 1 ). The time course of agmatine uptake into cells expressing EMTh deserves a mention (Fig. 4) . After about 2 h, the intracellular agmatine declines. This is unusual and has not been observed in our laboratory with other substrates. The data could be satisfactorily modeled with the variable k in as a function of time (k in ϭ k 1 Ϫ k 2 ⅐ t) and the constant k out . The merit of this definition of k in -although it probably makes no sense in terms of a cellular mechanism and a more complex definition may be necessary-is the suggestion that uptake capacity decreases over time. We speculate that agmatine triggers changes that eventually affect the carrier protein.
Further work is necessary to clarify this phenomenon.
Uptake of [ 14 C]agmatine was studied previously with synaptosomes from whole rat brain, at a pH of 7.2 (Sastre et al., 1997) . The transport mechanism was independent of Na ϩ and had an apparent K m of 19 mM. Whereas 1 mM noradrenaline or dopamine did not inhibit uptake of 0.1 mM agmatine significantly, nonspecific Ca 2ϩ channel blockers Co 2ϩ or Cd 2ϩ at 1 mM or verapamil at 0.1 mM did so. Noncompetitive inhibition was also achieved by imidazoline receptor antagonists idazoxan and phentolamine (K i ϭ 240 M for the latter). Sastre et al. (1997) concluded that agmatine may be transported through some type of cation channel, especially a Ca 2ϩ channel. However, from our point of view, the agmatine transport mechanism in rat brain may well correspond to either OCT2 or EMT for the following reasons. 1) Affinities may have been underestimated, since the uptake rates at 10 min were not initial any more. This may account for the relatively high K m and the lack of effect of noradrenaline and dopamine. 2) Organic cation transport has been shown to be sensitive to heavy metal ions (Katsura et al., 1993) . 3) As a large, hydrophobic compound, verapamil likely blocks all non-neuronal monoamine transporters, as demonstrated for EMTh (Martel et al., 2001) . 4) With a K i of 5 M, phentolamine is a relatively potent inhibitor, e.g., of EMTh (Grü ndemann et al., 2002). 5) Both EMT and OCT2 have been detected in brain (Grü ndemann et al., 1997 (Grü ndemann et al., , 1998b Busch et al., 1998; Wu et al., 1998; Mooslehner and Allen, 1999) . However, the precise localization still has to be established firmly. In the end, additional work is necessary to resolve whether the agmatine transport mechanism from rat brain synaptosomes is in fact EMT or OCT2, and whether distribution of agmatine correlates with transporter expression.
In a recent study with SK-MG-1 cells, an agmatine transport mechanism with a K m of 8.6 M and a V max of 63 nmol min Ϫ1 mg of protein Ϫ1 was observed (Molderings et al., 2001) . Agmatine uptake was independent of Na ϩ and could be inhibited neither by corticosterone nor by O-methylisoprenaline, typical inhibitors of EMT. It was concluded that EMT, among others, is not responsible for agmatine uptake into SK-MG-1 cells. This is difficult to reconcile with our data, however, since EMT is functionally expressed in this cell line (Streich et al., 1996) . Thus, although the available data suggest that in SK-MG-1 cells, a transporter other than EMT or OCT2 is responsible for agmatine uptake, some additional verification is desirable. In this respect, the remarkably steep dependence of agmatine uptake on pH may serve as a distinctive functional marker of the non-neuronal monoamine transporters. Other recent studies with cultured cells suggest the existence of a transporter which, in contrast to the non-neuronal monoamine transporters, accepts putrescine as substrate (Cabella et al., 2001; del Valle et al., 2001; Satriano et al., 2001 ). The molecular identity of this carrier is presently unkown. Molecular identification of transporters of agmatine will help to explore the versatile actions of this transmitter. For example, it has been shown that intracellular agmatine, via induction of antizyme, effectively suppresses synthesis and uptake of polyamines (Satriano et al., 1998) . Since the resulting depletion of polyamines inhibits cellular proliferation, agmatine may have a role as tumor suppressor. Interestingly, it has been suggested that agamatine could be selectively targeted to rapidly proliferating cells by an increase in membrane transport capacity (Satriano et al., 1999) . Defining an agmatine transport system is an important aspect of this hypothesis.
In conclusion, we have identified agmatine transport proteins on a molecular level. OCT2 and EMT both from rat and human efficiently, specifically, and bidirectionally translocate agmatine across the plasma membrane. By contrast, transport of agmatine by the structurally related carrier OCT1 is less efficient. From here on, pharmacological targeting of OCT2 and EMT may help to elucidate the pleiotropic functions of agmatine as a signaling substance. Clearly, a better understanding of agmatine physiology is indispensable for the development of new therapeutic strategies.
